Abstract:Xeroderma pigmentosum (XP) is a rare autosomal recessive disease caused by pathogenic variants in seven nucleotide excision repair genes (XPA to XPG) and POLH involved in translesion synthesis. XP patients have a >1000-fold increased risk for sunlight-induced skin cancers. Many Japanese XP-A patients have severe neurological symptoms due to a founder variant in intron 3 of the XPA gene. However, in the United States we found XP-A patients with milder clinical features. We developed a simple scoring scale to assess XP-A patients of varying neurological disease severity. We report 18 XP-A patients examined between 1973 and 2023 under an IRB approved natural history study. Using our scale, we classified our XP-A cohort into severe (n = 8), intermediate (n = 5), and mild (n = 5) disease groups at age 10 years. DNA repair tests demonstrated greatest reduction of DNA repair in cells from severe patients as compared to cells from mild patients. Nucleotide sequencing identified 18 germline pathogenic variants in the 273 amino acid, 6 exon-containing XPA gene. Based on patient clinical features, we associated these XPA variants to severe (n = 8), intermediate (n = 6), and mild (n = 4) clinical phenotypes in the patients. Protein structural analysis showed that nonsense and frameshift premature stop codon pathogenic variants located in exons 3 and 5 correlated with severe disease. Intermediate disease correlated with a splice variant at the last base in exon 4. Mild disease correlated with a frameshift variant in exon 1 with a predicted re-initiation in exon 2; a splice variant that created a new strong donor site in intron 4; and a large genomic deletion spanning exon 6. Our findings revealed correlations between disease severity, DNA repair capacity, and XPA variant type and location. In addition, both XPA alleles contributed to the phenotypic differences in XP-A patients. Xeroderma pigmentosum, (XP), is a rare autosomal recessive inherited disease. Exposure to ultraviolet radiation greatly increases the risk of developing skin cancers and premature aging features in XP patients. In Japan, most XP-A patients have a founder variant in intron 3 of the XPA gene and experience severe neurological symptoms and death at an early age. However, in our cohort we identified different germline variants in the XPA gene associated with severe and mild clinical features in the patients. To assess XP-A patients with a wider range of disease severity, we developed a simple neurological scoring scale. Using an age of evaluation of 10 years, we categorized phenotypic differences among our 18 XP-A patients and classified them into severe, intermediate, and mild disease groups. Using this scale, we associated these 18 pathogenic variants with severe (n = 8), intermediate (n = 6), and mild (n = 4) clinical phenotypes in the XP-A patients. As a result, our scale helps predict neurological severity and mortality, making it a useful tool for general clinical practice and genotype-phenotype studies. This allowed us to correlate neurological severity with the type, location, and cellular function of XPA germline pathogenic variants.

[Siblings with xeroderma pigmentosum group A showing mild cutaneous and various neurological manifestations]

Different germline variants in the XPA gene are associated with severe, intermediate, or mild neurodegeneration in xeroderma pigmentosum patients

A 10-year follow-up of a child with mild case of xeroderma pigmentosum complementation group D diagnosed by whole-genome sequencing

Whole-exome sequencing and host cell reactivation assay lead to a diagnosis of xeroderma pigmentosum group D with mild ultraviolet radiation sensitivity

XPC initiation codon mutation in xeroderma pigmentosum patients with and without neurological symptoms

The present status of xeroderma pigmentosum in Japan and a tentative severity classification scale

Neurological disease in xeroderma pigmentosum: prospective cohort study of its features and progression

Characteristics of Xeroderma Pigmentosum in Japan: Lessons From Two Clinical Surveys and Measures for Patient Care

Unexpected extradermatological findings in 31 patients with xeroderma pigmentosum type C

Xeroderma pigmentosum: man deprived of his right to light

Adult-Onset Neuropsychiatric Symptoms as the Presenting Feature of Xeroderma Pigmentosum Group G: A Report of a Rare Case

Identification of a ERCC5 c.2333T>C (L778P) Variant in Two Tunisian Siblings With Mild Xeroderma Pigmentosum Phenotype

Whole Exome Sequencing of a Patient with a Milder Phenotype of Xeroderma Pigmentosum Group C

Physical, oral, and swallowing functions of three patients with type a xeroderma pigmentosum: a report of three cases

Novel mutation identified in the DDB2 gene in patients with xeroderma pigmentosum group-E

Stomatological Findings In A Cluster Of Xeroderma Pigmentosum: Description And Comparison After A Period Of 12 Years.

Clinical and Molecular Epidemiological Study of Xeroderma Pigmentosum in China: A Case Series of 19 Patients

Xeroderma pigmentosum--Cockayne syndrome complex: a further case

A novel missense variant and multiexon deletion causing a delayed presentation of xeroderma pigmentosum, group C

Patients with xeroderma pigmentosum complementation groups C, E and V do not have abnormal sunburn reactions

A new XPC gene splicing mutation has lead to the highest worldwide prevalence of xeroderma pigmentosum in black Mahori patients